维普期刊资源整合服务平台（V6.5）

99篇 您的检索式：作者名="Curran WJ"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone.	Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M	2013	中国神经肿瘤杂志2013，11，1：	8
2	Long-term benefit is observed in a phase Ⅲ comparison of sequential vs concurrent chemoradiation for patients with unresected stage Ⅲ NSCLC: RTOG 9410显示文摘	Curran WJ Scott CB Langer CJ	2003	Proc Am Soc Clin Oncol2003，22，：	1
3	Sequential vs concurrent chemoradiation for wtage Ⅲ non-small cell lung cancer:Randomized phase Ⅲ trial RTOG 9401显示文摘	Curran WJ Jr Paulus R Lanqer CJ	2011	J Natl Cancer Inst2011，103，19：	1
4	Hyperfractionated radiotherapy for lung cancer显示文摘	Ggreessen EL Curran WJ	2000	Curt Oncol Rep2000，2，1：	1
5	Invasive thymoma:the role of mediastinal irradiation following complete or incomplete surgical resection 显示文摘	Curran WJ Komstein MJ Brooks JJ	1988	J Clin Oncol1988，6，：	1
6	Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage lIl NSCLC: RTOG 9410显示文摘	CURRAN WJ SCOTT CB LANGER C J	2003	Proc Am Soc Clin Oncol2003，22，1：	1
7	A phase I1 trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer显示文摘	Anne PR Curran WJ Jr	2002	Semin Radiat Oncol2002，12，1：	1
8	A phase Ⅱ study of cetuximab in combination with chemoradiation in patients with stage ⅢA-B Non-small Cell Lung Cancer:a report of the two year and median survival for the RTOG 0324 trial显示文摘	Blumenschein GR Paulus R Curran WJ	2008	J Clin Oncol2008，26，：	1
9	Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy?显示文摘	Curran WJ Herbert SH Stafford PM	1992	Int J Radiat Oncol Biol Phys1992，24，1：	1
10	Phase II studyof cetuximab in combination with chemoradiation in patients withstage II A/B non-small-cell lung cancer: RTOG 0324显示文摘	Blumenschein GR Jr Paulus R Curran WJ	2011	J ClinOncol2011，29，17：	1
11	Treatment of locally advanced non-small celllung cancer : what we have arid have not learned over the pastdecade显示文摘	Curran WJ Jr	2005	Semin Oncol2005，32，23：	1
12	Hyperfractionated radiotherapy for lung cancer显示文摘	Ggreessen EL Curran WJ	2000	Curr Oncol Rep2000，2，1：	1
13	A phase H study of cetuximab(C225) in combination with chemoradiation (CRT) in patients ( PTS ) with stage m A/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival for the RTOG0324 trial 显示文摘	Blumcnschein GR Paulus R Curran WJ Robert F Fossella FV Wasik MW	2008	J Clin Oncol2008，26，15：	1
14	Long-term benefit is observed in a phase Ⅲ comparison of sequential vs concurrent chemo-radiation for patients with unresected stage Ⅲ nsclc:RTOG 9410显示文摘	Curran WJ Scott CB Langer CJ	2003	Proc Am Soc Clin Oncol2003，22，62：	1
15	Phase Ⅲ comparision of sequential vs concurrent chemoradiation therapy for patientswith unresectable stage Ⅲ non2small2cell lung can-cer initial report of RTOG 9410显示文摘	Scott C Langer C	2000	Proc Am Soc Clin Oncol2000，19，6：	1
16	RTOG 0324: A phase II study of eetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small eell lung cancer (NSCLC)-assoeiation between EGFR gene copy number and patients' outcome显示文摘	Olsen CC Paulus R Komaki R Garcia MV Dziadziuszko R Curran WJ	2008	J Clin Onenl2008，26，15：	1
17	Detailed chemical kinetic mechanisms for combustion of oxygenated fuels显示文摘	Fisher EM Pitz WJ Curran HJ		0，，：	1
18	Long-term benefit is observed in a phase Ⅲ comparison of sequential vs con-current chemoradiation for patients with unresected stage Ⅲ NSCLC:RTOG 9410 显示文摘	Curran WJ Scott CB Langer CJ	2003	Proc Am Soc Clin Oncol2003，22，：	1
19	Sequential vs concurrent che-moradiation for stage DI non - small cell lung cancer randomizedphase HI trial RTOG 9401 显示文摘	Curran WJ Jr Paulus R Lanqer CJ	2011	J Natl Cancer Inst2011，103，19：	1
20	Long-term benefit is observed in a phase Ⅲ comparison of sequential vs concurrent chemo-radiation for patients with unresected stage Ⅲ nsclc:RTOG 9410显示文摘	Scott CB Langer CJ	2003	Proc Am Soc Clin Oncol2003，22，62：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示